The agreement combines Covidien’s expertise in radiopharmaceuticals and regulatory issues with Positron’s expertise in automation and radiopharmaceuticals.
Positron and Covidien said that automating the distribution of radiopharmaceuticals has many benefits, ranging from worker safety to cost savings to enhanced customer service.
Positron COO John Zehner said that the company continues to provide solutions to the molecular imaging community and the agreement provides Positron with various advantages and additional resources.
Positron is focused on nuclear cardiology which utilises its proprietary product line to provide solutions to the nuclear medicine community ranging from imaging to radiopharmaceutical distribution.
Positron products include Attrius, a PET imaging device; Pulse, a SPECT imaging device; Nuclear Pharm-Assist, an automated radiopharmaceutical distribution device; and Tech-Assist, a radiopharmaceutical injection shield.
